Clinical Trial Update: A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1) [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging pharmacokinetics and safety study of GWP42003-P in children with Dravet syndrome completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dravet Syndrome
• Epilepsy

Drugs mentioned

• GWP42003-P

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Epilepsy, Dravet Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2018-07-19